The Global Health Body Issues Warning Over Critical Shortage of Weight-Loss Jabs
Less than a tenth of people eligible to benefit from obesity jabs such as Wegovy are able to get them, states the World Health Organization as it issues its first advice on the drugs.
Considering more than one billion individuals worldwide currently obese, it is calling for broader and more equitable availability to these injectable treatments.
Based on projections, in excess of 2,000,000,000 could be obese by 2030 without intervention.
"The new guidance recognises that excess weight is a chronic disease that can be treated with holistic and ongoing support," remarked WHO director-general Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and distribution challenges are key hurdles to universal access to the treatments that can help people shift substantial body mass, explains the body.
Weight-Loss Drug Scarcity
Despite the current most optimistic outlook, the production of such drugs might only reach around 100 million people – fewer than 10% of the global need, per the WHO.
The recommendation urges nations and manufacturers to expand access, via measures such as patent sharing.
A patent on the active ingredient – the main ingredient of the drug Wegovy – is set to lapse in several nations in 2026.
How Obesity Jabs Function
GLP-1 drugs imitate a biological compound to reduce digestion speed, reduce hunger and enhance feelings of fullness so individuals reduce food intake.
Individuals commonly begin shedding pounds after several weeks of starting on the once-weekly jabs.
Evidence indicates patients may regain a significant portion within a year of stopping the medication, when their usual food cravings resume.
Being overweight or obese raises your risk for experiencing diseases, including diabetes, cardiovascular issues, stroke, and certain cancers.
Excess weight concerns people in every country and was linked to 3.7 million deaths worldwide in 2024, per the WHO.
